HCA Healthcare price target raised to $330 from $315 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on HCA Healthcare to $330 from $315 and keeps an Outperform rating on the shares. The firm notes HCA reported strong Q4 results and issued an impressive outlook for 2024, as the company continues its steady rate of growth as seasonality normalizes. Overall, Oppenheimer continues to favor HCA, which has continued to generate steady growth despite a challenging and volatile industry backdrop.